Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021
• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients. • Preclinical pipeline disclosed at Innovation Days : UCART20x22 for B-cell malignancies, UCARTMESO(targeting…